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OBJECTIVE—Recently, the Nateglinide and Valsartan in Impaired Glucose Tolerance Out-
comes Research Trial demonstrated that treatment with the angiotensin receptor blocker (ARB)
valsartan for 5 years resulted in a relative reduction of 14% in the incidence of type 2 diabetes in
subjects with impaired glucose metabolism (IGM). We investigated whether improvements in
b-cell function and/or insulin sensitivity underlie these preventive effects of the ARB valsartan in
the onset of type 2 diabetes.
RESEARCH DESIGN AND METHODS—In this randomized controlled, double-blind,
two-centerstudy,theeffectsof26weeksofvalsartan(320mgdaily;n=40)orplacebo(n=39)on
b-cell function and insulin sensitivity were assessed in subjects with impaired fasting glucose
and/or impaired glucose tolerance, using a combined hyperinsulinemic-euglycemic and hyper-
glycemic clamp with subsequent arginine stimulation and a 2-h 75-g oral glucose tolerance test
(OGTT). Treatment effects were analyzed using ANCOVA, adjusting for center, glucometabolic
status, and sex.
RESULTS—Valsartan increased ﬁrst-phase (P = 0.028) and second-phase (P = 0.002) glucose-
stimulated insulin secretion compared with placebo, whereas the enhanced arginine-stimulated
insulinsecretion wascomparable betweengroups(P=0.25).In addition,valsartan increasedthe
OGTT-derived insulinogenic index (representing ﬁrst-phase insulin secretion after an oral glu-
coseload;P=0.027).Clamp-derivedinsulinsensitivitywassigniﬁcantlyincreasedwithvalsartan
compared with placebo (P = 0.049). Valsartan treatment signiﬁcantly decreased systolic and
diastolic blood pressure compared with placebo (P , 0.001). BMI remained unchanged in both
treatment groups (P = 0.89).
CONCLUSIONS—Twenty-six weeks of valsartan treatment increased glucose-stimulated
insulin release and insulin sensitivity in normotensive subjects with IGM. These ﬁndings may
partly explain the beneﬁcial effects of valsartan in the reduced incidence of type 2 diabetes.
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T
he association between insulin resis-
tance, type 2 diabetes, and inappropri-
ate activation of the renin-angiotensin
system (RAS) has been described exten-
sively (1,2). These relationships are not
solely attributed to systemic RAS compo-
nents, which mainly are derived from the
kidney, liver, and lung.Additional activa-
tion of local RAS in adipocytes and the
pancreas also may contribute to impaired
insulin sensitivity and b-cell function
(3,4). Recent trials (5,6) have suggested
that RAS inhibition with angiotensin II
receptor blockers (ARBs) or ACE inhibi-
tors may reduce the incidence of new-
onset type 2 diabetes. However, these
studies mainly were performed in hyper-
tensive patients, and the onset of type 2
diabeteswasnota prespeciﬁed end point.
More recently, the large-scaled, prospec-
tive Nateglinide and Valsartan in Im-
paired Glucose Tolerance Outcomes
Research (NAVIGATOR) trial addressed
the potential of the ARB valsartan to pro-
tect individuals with impaired fasting
glucose (IFG) and/or impaired glucose
tolerance (IGT) against type 2 diabetes
and cardiovascular disease (7). After a
treatment period of 5 years, valsartan de-
creased the onset of type 2 diabetes by
14%. However, the underlying mecha-
nisms are incompletely understood.
One of the underlying mechanisms
may involve a positive effect of RAS
blockers on insulin sensitivity (8). In
part, these effects may be a result of he-
modynamic changes, increasing skeletal-
muscle blood ﬂow, with augmented
glucose and insulin delivery to insulin-
sensitive tissues (4). In addition, RAS
blockade may exert direct effects on
skeletal muscle and adipose tissue, such
as increased adipocyte differentiation (9),
which may increase insulin-induced glu-
cose uptake in skeletal muscle (3,4). Fur-
thermore, treatment with an ARB or ACE
inhibitor may directly affect b-cell func-
tion. In vitro, blocking the RAS with an
ACE inhibitor or ARB prevented the dele-
terious effects of hyperglycemia on b-cell
function (10,11). In vivo, however, lim-
ited information regarding the effect of
RAS blockade on b-cell function is avail-
able. Short-term treatment (6 weeks) with
valsartan had no effect on b-cell function
(12), whereas Suzuki et al. (13) demon-
strated that 3 months of treatment with
the ARB candesartan increased ﬁrst-phase
insulin secretion, assessed during an oral
glucose tolerance test (OGTT).
We hypothesized that both improve-
ment of insulin sensitivity and b-cell
function may underlie the protective ef-
fect of ARB intervention in the develop-
ment of type 2 diabetes in subjects with
impaired glucose metabolism (IGM). We
tested this hypothesis by conducting a
randomized controlled trial in which indi-
viduals with IGM were randomly assigned
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ORIGINAL ARTICLEto receive either valsartan (320 mg once
daily) or placebo for 26 weeks. Insulin
sensitivity and various aspects of b-cell
function were assessed using both the gold
standard hyperinsulinemic-euglycemic
and hyperglycemic clamp as well as an
OGTT.
RESEARCH DESIGN AND
METHODS—In this randomized con-
trolled, double-blind study (Vrije Uni-
versity Medical Center, Maastricht
University Medical Center, the Nether-
lands),patientswithIFGand/orIGTwere
randomlyassignedtovalsartan(n=40)or
placebo (n = 39). Patients received 160
mg valsartan or placebo once daily for 2
weeks. Thereafter, the dosage was dou-
bled to 320 mg q.d. valsartan or placebo
for the subsequent 24 weeks. Before and
after 26 weeks of treatment, we performed
a combined hyperinsulinemic-euglycemic
and hyperglycemic clamp with arginine
stimulation and a 2-h 75-g OGTT.
The primary end point was the effect
of valsartan versus placebo on clamp-
measured b-cell function. The secondary
end point was the effect of valsartan ver-
sus placebo on clamp-measured insulin
sensitivity,bloodpressure,fastingplasma
glucose (FPG), HbA1c, fasting plasma in-
sulin (FPI), body weight, waist, safety,
and tolerability.
Participants were recruited by adver-
tisements in newspapers. After obtaining
written informed consent, 259 subjects
underwent a screening OGTT. Subjects
withIFG(FPG$6.1and,7.0mmol/Lor
FPG$5.6and,7.0mm ol/La ndafam ily
history of type 2 diabetes) and/or IGT (2-h
plasma glucose level $7.8–11.1 mmol/L)
were eligible. Individuals only were al-
lowed to use lipid-lowering medication
(statins). Subjects with a blood pressure
.140/90 mmHg were treated with 5 mg
amlodipine. If blood pressure persisted
.140/90 mmHg, amlodipine was in-
creased to 10 mg, followed by 12.5 mg
hydrochlorothiazide and/or 25 mg carve-
dilol. Subjects with blood pressure ,140/
90 mmHg were included in the study. A
total of 43 subjects with IFG (51% male),
11 subjects with IGT (46% male), and 25
subjects with IFG/IGT (56% male) were
enrolled.Exclusioncriteriawereexcessal-
cohol intake, hepatitis and/or pancreatitis,
abnormal liver and renal function tests,
and recent changes in weight ($5%
change). The study was conducted ac-
cording to the Declaration of Helsinki
andwasapprovedbythelocalethicscom-
mittee.
Clamp
A hyperinsulinemic-euglycemic and hy-
perglycemic clamp with arginine stimu-
lation was performed to assess insulin
sensitivity and secretion. During the
hyperinsulinemic-euglycemic clamp, the
insulin infusion rate was maintained at
40 mU z min
21 z m
2 body surface area.
After an hour resting period, the hyper-
glycemic clamp was started by giving a
glucose bolus, which increased the blood
glucose concentration to 15.0 mmol/L.
Steady-state blood glucose concentra-
tions at 15.0 mmol/L were sustained
with a variable 20% glucose infusion for
80 min. Thereafter, 5.0 g arginine was ad-
ministered to measure maximum insulin
secretory capacity at a steady-state blood
glucose concentration of 15.0 mmol/L.
OGTT and blood pressure
A 75-g 2-h OGTT was performed. Blood
samples were obtained at seven time
points to determine glucose and insulin.
Blood pressure was measured using an
Omron 705 CP (Omron; Shiokoji Hori-
kawa, Shimogyo-ku, Japan) on the non-
dominant arm, after a 15-min rest.
Biochemical analyses
Glucose concentrations were determined
using a hexokinase method (Gluco-quant;
Roche Diagnostics, Mannheim, Germany).
HbA1c was measured by cation-exchange
chromatography (reference values: 4.3–
6.1%; Menarini Diagnostics, Florence,
Italy). Serum insulin concentrations were
quantiﬁed using immunometric assays
(Advia,Centaur; Siemens Medical Solutions
Diagnostics, Deerﬁeld, IL). The intra-assay
precision for insulin ranged from 3 to 4%
over a mean range of 0.02–1.5 nmol/L.
Calculations
Hyperinsulinemic-euglycemic clamp.
Insulin sensitivity was deﬁned as the glu-
cose infusion rate (M value, mg z min
21 z
kg
21) during the last 30 min of the hyper-
insulinemic-euglycemic clamp, with a
steady-state blood glucose concentration of
5.0 mmol/L. The M value was used because
correction for steady-state insulin concen-
trations (M/I) did not alter the results.
Hyperglycemic clamp. First-phase in-
sulin secretion was calculated as the
insulin area under the curve (AUC;
pmol z min
21 z L
21)d u r i n gt h eﬁrst 10
min after the glucose bolus, increasing
glucose levels to 15.0 mmol/L. Second-
phase insulin secretion was calculated as
the insulin AUC during 70 min after ﬁrst-
phaseinsulinsecretion.Arginine-stimulated
acute insulin response (AIRarg) was calcu-
latedastheinsulinAUCduringtheﬁrst10
min after the arginine bolus and adminis-
tered at t = 80 min during the hyperglyce-
micclamp.Thedispositionindex(mgzL)/
(nmol z kg), correcting insulin secretion
for insulin sensitivity, was calculated by
multiplying ﬁrst- and second-phase glu-
cose-stimulated insulin secretion with the
M value.
OGTT. First-phase glucose-stimulated
insulin secretion (the insulinogenic in-
dex) was calculated as the ratio of the
increment of insulin 30 min after the oral
glucose load to the increment of blood
glucose concentration over the ﬁrst 30
min [(I30 2 I0)/G30 2 G0]. Insulin sensi-
tivitywascalculatedusingtheinsulinsen-
sitivity index composite (ISIcomp: 10.000/
!G0 z I0 z Gmean z Imean). The mean arterial
pressure(MAP)wascalculatedasdiastolic
blood pressure + [1/3 z (systolic blood
pressure 2 diastolic blood pressure)].
Statistical analysis
The primary end point was change in
ﬁrst-phase glucose-stimulated insulin se-
cretion after 26 weeks of treatment with
valsartan or placebo, which was calculated
as the AUC of insulin and/or C-peptide
over the ﬁrst 10 min of the hyperglycemic
clamp.WeassumedadeclineinAUCﬁrst-
phaseinsulinsecretionof2.5%insubjects
withIFGorIGT(14)andanimprovement
of b-cell function by valsartan of 10% (SD
50%). A sample size of 68 subjects would
provide 80% power to detect a 10% in-
crease in valsartan compared with pla-
cebo, taking into account correction for
confounders. Assuming a drop-out rate
of20%,80subjectsneededtobeincluded.
Treatment effects were assessed by
ANCOVA,with adjustmentfor center, sex,
glucometabolic status (i.e., IFG and/or
IGT), and baseline measurement. Univar-
iate correlations (Spearman r) were used
toexamineassociationswithchangesinin-
sulin sensitivity and insulin secretion. All
statistical analyses were performed using
SPSS for Windows, version 15.0 (SPSS,
Chicago, IL). P , 0.05 was considered sta-
tistically signiﬁcant. Data are expressed as
means 6 SEM or, in the case of skewed
distributions, as median (interquartile
range) for numerical variables and as pro-
portions for categorical variables.
RESULTS
Subject characteristics
Baseline characteristics of the study pop-
ulation randomly assigned to valsartan or
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Valsartan in the PRESERVE studyplacebo are listed in Fig. 1. The valsartan
group included 52% subjects with IFG
and 48% subjects with IFG/IGT, and the
placebo group included 56% subjects
with IFG and 44% subjects with IFG/
IGT. The study medication was well tol-
erated; there were no serious adverse
events. All randomly assigned individuals
completed the study. A total of 15% of
subjects randomly assigned to valsartan
used antihypertensive agents compared
with28%ofsubjectsintheplacebogroup
(P=0.15).At26weeks,valsartan,relative
toplacebo,resultedinasigniﬁcantreduc-
tioninsystolicanddiastolicbloodpressure
(Table 1) and MAP (28.4 6 1.6 mmHg
vs. 21.7 6 1.0 mmHg,P , 0.001,respec-
tively). Furthermore, 2-h postload glucose
tended to increase after placebo treatment
compared with valsartan treatment (P =
0.09). Twenty-six weeks of treatment had
no effect on BMI, waist circumference,
FPG, HbA1c,F P I ,a n dl i p i dm e t a b o l i s m
(Table 1).
b-Cell function
At baseline, there were no differences in
insulin secretion between the two treat-
ment groups (ﬁrst phase: 2.4 6 0.3 vs.
2.6 6 0.4 nmol z min
21 z L
21, P = 0.66;
second phase: 21.7 6 1.8 vs. 27.2 6 2.9
nmol z min
21 z L
21, P = 0.13; arginine
stimulated: 20.0 6 1.6 vs. 24.7 6 2.1
nmol z min
21 z L
21, P = 0.10; valsartan
vs. placebo, respectively) At 26 weeks,
valsartan versus placebo increased ﬁrst-
and second-phase glucose-stimulated in-
sulin secretion during the hyperglycemic
clamp, whereas arginine-stimulated insu-
lin secretion was comparable between
groups (Fig. 2). The disposition index
tended to be increased after valsartan
treatment compared with placebo, al-
thoughthisdidnotreachstatisticalsignif-
icance (5 6 14 vs. 230 6 18 [nmol z
min
21 z L
21] 3 [mg z kg
21 z min
21],
P = 0.12, respectively). In accordance
with clamp-measured b-cell function,
valsartan treatment signiﬁcantly in-
creased the insulinogenic index, reﬂect-
ing an increased ﬁrst-phase insulin
secretion during the OGTT (Fig. 2).
Insulin sensitivity
Twenty-six-week valsartan treatment sig-
niﬁcantly increased clamp-derived insu-
lin sensitivity compared with placebo
(Fig. 3). There were no between-group
differencesininsulinplasmalevelsduring
the hyperinsulinemic-euglycemic clamp.
Correcting the M value for prevailing
insulin levels did not alter the results. In-
terestingly, the difference in OGTT-
derived insulin sensitivity did not reach
statistical signiﬁcance (Fig. 3).
Determinants of insulin sensitivity
and b-cell function
The change in clamp-derived insulin sen-
sitivity was inversely correlated with the
change in MAP (r = 20.30, P = 0.02).
However, no signiﬁcant correlations
were found between MAP and b-cell
function parameters (ﬁrst-phase insulin
secretion: r = 20.028, P = 0.82; second-
phase insulin secretion: r = 20.006, P =
0.96; IGIOGTT: r = 20.08, P =0 . 5 1 ) .N o
other determinants were detected that
could explain the change in insulin sensi-
tivity and b-cell function.
CONCLUSIONS—The current study
demonstrated that 26 weeks of valsartan
treatment improved various aspects of
b-cell function and insulin sensitivity,
compared with placebo, in individuals
with IGM. Importantly, all subjects had
blood pressure values within the normal
range at baseline, with or without con-
comitant antihypertensive therapy.
Recently, the DREAM (Diabetes Re-
duction Assessment with Ramipril and
Rosiglitazone Medication) trial (15) and
the NAVIGATOR trial speciﬁcally ad-
dressed the effect of prolonged ACE in-
hibitor and ARB treatment on incident
type 2 diabetes in large populations of in-
dividuals with IGM. In the DREAM trial,
15 mg q.d. ramipril, given for 3 years,
nonsigniﬁcantly reduced the incidence
of type 2 diabetes by 9%. During this rel-
ativelyshortinterventionperiod, individ-
uals treated with ramipril were more
likely to revert from IGM to normoglyce-
mia, and their postload glucose levels
were signiﬁcantly reduced compared
with placebo (15). In the NAVIGATOR
trial, 160 mg q.d. valsartan, given for 5
years, not only reduced fasting and post-
load glucose after an OGTT but also re-
duced the incidence of type 2 diabetes by
14% (11). However, in these trials no un-
derlying mechanisms were addressed.
Our data, obtained in a comparable
high-risk population, suggest that im-
provement in b-cell function, as well as
in insulin sensitivity, may contribute to
the effect of ARBs to reduce the incidence
of type 2 diabetes.
Previously, short-term (6 weeks) low
doses of valsartan (80 mg q.d.) did not
affect clamp-measured b-cell function in
subjects with IGT (12). In contrast, other
studies (13) found increased OGTT-
derived ﬁrst-phase insulin secretion af-
ter 3 months of candesartan treatment
(8 mg q.d.) in subjects with IGT and
hypertension. Our study is the ﬁrst to
Figure 1—Inclusion ﬂowchart and baseline characteristics of the study population. Data rep-
resent means 6 SE.
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van der Zijl and Associatessimultaneously measure the effects of 26
weeks of high-dose valsartan treatment
on multiple aspects of b-cell function us-
ingthehyperglycemicclampmethod.We
f o u n da ni n c r e a s ei nc l a m p - m e a s u r e d
glucose-stimulated insulin secretion,
with no alterations in arginine-stimulated
insulin secretion. Furthermore, similar
to Suzuki et al. (13), the insulinogenic
index, reﬂecting ﬁrst-phase insulin
secretion during an OGTT, increased
with valsartan compared with placebo.
The discrepant ﬁndings between the cur-
rent study and the study of Bokhari et al.
(12), who did not ﬁnd an effect on clamp-
measured b-cell function after ARB treat-
ment, may be explained by differences in
exposure time and the used dosage.
In the current study, and in the study
of Suzuki et al. (13), treatment-related al-
terations in clamp- and OGTT-derived
b-cell function were unrelated to changes
in blood pressure, suggesting that valsar-
tan may directly affect pancreatic islets,
thereby increasing insulin secretion. Mo-
lecular mechanisms explaining this ob-
servation have been addressed in vitro
and in vivo in rodent studies (10,11). In
the pancreas, a local RAS is present, with
the expression and localization of angio-
tensinogenandAT1receptorsparticularly
localized in the islets and endothelial
cells of the pancreatic vasculature (16).
A relationship between RAS activation
andhyperglycemiawasassessedinvitro,
where exposure to high glucose concen-
trationsupregulatedRAScomponentsin
rodent and human pancreatic b-cells
(10). Glucose-induced RAS activation
resulted in increased reactive oxygen
species production, tissue inﬂamma-
tion, and increased cell proliferation
and apoptosis (11). Furthermore, RAS
blockade prevented these deleterious ef-
fectsofhyperglycemiaonb-cellfunction
(10).
Inadditiontoimprovementsinb-cell
function, we found that valsartan relative
to placebo increased insulin sensitivity,
as assessed with the hyperinsulinemic-
euglycemic clamp. However, the ob-
served increase of OGTT-derived insulin
sensitivity (ISIcomp) after valsartan treat-
ment did not reach statistical signiﬁ-
cance. After an OGTT, there is a great
intra- and intersubject variability in glu-
cose uptake and hepatic glucose produc-
tion. Therefore, although OGTT-derived
insulin sensitivity may take into account
more physiological contributing mecha-
nisms, the variability by far exceeds that
of clamp-measured insulin sensitivity
(17).
Clamp-measured insulin sensitivity
provides an accurate estimate of whole-
body insulin sensitivity, which is largely
determined by skeletal muscle because
the used insulin levels almost fully sup-
press endogenous glucose production
(18). Several mechanisms may underlie
the valsartan-induced improvement in
peripheral insulin sensitivity. First,
Table 1—Valsartan-induced changes in glucometabolic variables
Valsartan Placebo P
n 40 39
BMI (kg/m
2)
Baseline 29.8 6 0.6 29.5 6 0.8
Post-treatment 29.9 6 0.7 29.7 6 0.8
Change 0.16 6 0.15 0.15 6 0.12 0.89
Waist (cm)
Baseline 101.8 6 1.7 102.4 6 2.0
Post-treatment 102.3 6 1.9 102.8 6 2.0
Change 0.7 6 0.7 0.2 6 0.5 0.56
Systolic blood pressure (mmHg)
Baseline 131 6 1.6 130 6 1.8
Post-treatment 117 6 1.9 127 6 2.0
Change 212.91 6 2.1 21.38 6 1.2 ,0.001
Diastolic blood pressure (mmHg)
Baseline 83 6 1.2 83 6 0.9
Post-treatment 75 6 1.3 81 6 1.2
Change 27.24 6 1.4 20.69 6 1.1 ,0.001
FPG (mmol/L)
Baseline 6.4 6 0.1 6.3 6 0.1
Post-treatment 6.3 6 0.1 6.3 6 0.1
Change 20.2 6 0.1 0 6 0.1 0.56
2-h Postload glucose (mmol/L)
Baseline 8.4 6 0.4 8.1 6 0.4
Post-treatment 8.5 6 0.5 8.9 6 0.4
Change 0.1 6 0.4 0.8 6 0.2 0.09
HbA1c (%)
Baseline 6.0 6 0.1 5.9 6 0.1
Post-treatment 5.9 6 0.1 5.9 6 0.1
Change 20.05 6 0.02 0.05 6 0.01 0.32
FPI (pmol/L)
Baseline 90.4 6 8.0 87.4 6 8.3
Post-treatment 90.2 6 7.7 91.0 6 9.0
Change 20.5 6 5.6 3.6 6 4.3 0.83
Total fasting cholesterol (mmol/L)
Baseline 5.4 6 0.14 5.3 6 0.17
Post-treatment 5.4 6 0.12 5.2 6 0.17
Change 20.01 6 0.1 20.11 6 0.12 0.33
HDL cholesterol (mmol/L)
Baseline 1.26 6 0.06 1.26 6 0.06
Post-treatment 1.23 6 0.06 1.26 6 0.06
Change 20.03 6 0.03 0.01 6 0.02 0.31
LDL cholesterol (mmol/L)
Baseline 3.49 6 0.12 3.37 6 0.13
Post-treatment 3.44 6 0.13 3.26 6 0.11
Change 20.04 6 0.08 20.11 6 0.08 0.31
Triglycerides (mmol/L)
Baseline 1.46 6 0.12 1.43 6 0.11
Post-treatment 1.61 6 0.11 1.58 6 0.15
Change 0.10 6 0.09 0.15 6 0.08 0.70
Data are means 6 SE unless otherwise indicated.
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Valsartan in the PRESERVE studyangiotensin II (AngII) decreases skeletal-
muscle blood ﬂow in humans (19). Ac-
cordingly, RAS blockade resulted in in-
creased forearm blood ﬂow (20), thereby
increasing glucose and insulin delivery to
skeletal muscle, which may lead to in-
creased glucose utilization. Second, in ro-
dents, AngII directly inhibited insulin
signaling in skeletal muscle (2), which
was counteracted by ARB treatment
(2,3). Finally, AngII may increase the
number of large insulin-resistant adipo-
cytes via inhibition of adipocyte differen-
tiation. RAS blockade reduced adipocyte
size and improved adipose tissue function
Figure 2—Effect of 26 weeks of valsartan (VAL) on clamp- and OGTT-derived measures of b-cell function. Changes in AUC ﬁrst-phase (A)a n d
second-phase(B)glucose-stimulatedinsulinsecretionandcombinedhyperglycemiaandarginine-stimulatedinsulinsecretion(C)andinsulinogenic
index(D) at 26 weeksof valsartan( )or placebo(PLB)(□).Data represent means 6SE or,inthe caseofnonnormallydistributed data,medians
(interquartile range).
Figure 3—Effect of 26 weeks of valsartan (VAL) treatment on clamp- and OGTT-derived insulin sensitivity. Changes in clamp-derived insulin
sensitivity (A) and OGTT-derived insulin sensitivity (B) at 26 weeks of valsartan ( )o rp l a c e b o( P L B )( □). Data represent means 6 SE.
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van der Zijl and Associatesin human adipocytes (9) and in rodents
(21). The underlying mechanisms of im-
provedinsulinsensitivityneedtobeinves-
tigated in future studies in humans.
TheeffectofARBtreatmentoninsulin
sensitivity might differ among the various
compounds. Hsueh et al. (22) recently
showed that telmisartan (160 mg q.d.,
16 weeks of treatment) did not affect in-
sulin sensitivity in obese, hypertensive,
normoglycemic individuals. Ideally, a
head-to-head comparison of different
ARBs in a randomized controlled trial is
needed to address the issue of whether
improvement in insulin sensitivity is a
class effect of ARBs or is conﬁned to spe-
ciﬁc agents. Furthermore, conﬂicting re-
sults have been published regarding the
protective effect of ARBs in addition to
blood pressure medication known to in-
duce type 2 diabetes (23,24). Therefore,
the glucometabolic beneﬁts of ARBs
might depend on the agent that is used,
the study population (a priori risk), con-
comitant medication, and the duration of
exposure.
Despite changes in insulin secretion
and action, there were no signiﬁcant
changes in FPG, FPI, and HbA1c.At r e n d
toward improvementin 2-h postload glu-
cose was observed in the valsartan group.
Thislackofchangesinclinicalvariablesof
glucose metabolism is in line with previ-
ous studies (8) and is likely to be a result
of thetreatment duration of these studies,
whichalllast,6months.Althoughpath-
ophysiological differences have been de-
scribed in the underlying defects of IFG
and/or IGT, in general, subjects with
IFG and/or IGT already are character-
ized by impaired insulin sensitivity and
b-cell function (25). This study was not
poweredtomeasuretheeffectofvalsartan
in individuals with IFG and IFG/IGT sep-
arately. Furthermore, we were not able to
detect a delay in the onset of type 2 di-
abetes, as seen in large clinical studies.
This might be a result of the treatment
time and limited power, although a high
dose of valsartan was used.
In conclusion, the current study
demonstrates that 26 weeks of treatment
with valsartan signiﬁcantly improved
glucose-stimulated insulin release and
insulin sensitivity in subjects with IGM.
These ﬁndings may partly explain the
beneﬁcialroleofvalsartaninloweringthe
risk of incident type 2 diabetes in com-
parable, high-risk populations. However,
the mechanisms underlying the valsartan-
induced improvements in b-cell func-
tion and insulin sensitivity remain to be
established and warrant further investi-
gation.
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